Clinical Scorecard: Evaluating the Efficacy of Reduced Fractionation in Stereotactic Body Radiotherapy for Malignant Adrenal and Renal Tumors

At a Glance

Key Highlights

• SBRT is an effective non-invasive alternative to surgery for RCC and AM, especially in inoperable patients or those refusing surgery.
• High BED (>100 Gy) delivered in 3-8 fractions achieves promising local control despite RCC's traditional radioresistance.
• SBRT treatment planning includes multiple CT scans for accurate tumor and organ-at-risk delineation with 3-5 mm margins.

Guideline-Based Recommendations

Diagnosis

• Confirm solid primary tumor or postsurgery clips via imaging.
• Use CT simulation scans in shallow breathing, deep inspiration, and end expiration for treatment planning.
• Evaluate tumor response using RECIST 1.1 criteria on follow-up CT scans.

Management

• Consider SBRT for patients with RCC or AM who are inoperable or refuse surgery.
• Prescribe median dose of 60 Gy in 3-8 fractions, aiming for BED10 > 100 Gy when possible.
• Use multidisciplinary team discussions to individualize treatment planning and delivery.

Monitoring & Follow-up

• Follow-up visits at 6 weeks post-treatment, then every 3 months with CT imaging.
• Assess toxicity using CTCAE v4.0 criteria.
• Monitor for local control, treatment response, progression-free survival, and overall survival.

Risks

• Potential adverse events include gastrointestinal toxicity such as duodenal ulcer requiring hospitalization and conservative management.
• Consider dose constraints for organs at risk (spine, bowel, gastric, duodenum, kidneys) to minimize toxicity.

Patient & Prescribing Data

23 patients with 25 lesions of RCC and AM, aged 18-80, ECOG 0-1, inoperable or refusing surgery

Median lesion volume 14.11 cm3; median dose 60 Gy over median 5 fractions; most patients received BED10 > 100 Gy with good local control and manageable toxicity

Clinical Best Practices

• Use multidisciplinary team approach for patient selection and treatment planning.
• Employ multiple CT simulation scans to accurately delineate tumor and organs at risk.
• Apply strict dose constraints to critical organs to reduce adverse events.
• Prescribe high BED doses to overcome radioresistance, especially in RCC.
• Monitor patients closely post-treatment with scheduled imaging and toxicity assessments.

References

• Incidence and treatment of RCC and AM
• SBRT as alternative to surgery
• Radiosensitivity of RCC and AM
• Underutilization and evolving role of SBRT in AM
• Dose constraints and treatment planning
• Adverse event criteria
• Tumor response evaluation criteria